Boston Scientific Corp. said Monday it is withdrawing its financial guidance for the first quarter and 2020, that it provided on Feb. 5, given the uncertainties related to the COVID-19 pandemic, which has caused the deferral of elective medical procedures. “This disruption, as well as others caused by the evolving COVID-19 pandemic and macroeconomic environment, are expected to negatively impact the company’s financial results,” the medical device maker said in a statement. “In addition, given the ongoing uncertainty of the scope and duration of the pandemic, the company is currently unable to estimate those specific impacts.” The stock, which is indicated up about 1% in premarket trading, has shed 32% over the past three months, while the S&P 500 has declined 21.1%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
- Livability: Nine U.S. towns worth visiting for their cool art scenes - August 17, 2022
- NerdWallet: Not your grandma’s stove…how can you buy stuff that doesn’t break right away? - August 17, 2022
- NerdWallet: Take advantage of these handy features in your bank app - August 17, 2022